No Detail Found!

Diagnostic utility of P53 in different grades of glioma

Author(s)
Fareeha Shahid Department of Histopathology, HBS Medical & Dental College,Islamabad,Pakistan
Ayesha Sarwar Department of Histopathology, HBS Medical & Dental College,Islamabad,Pakistan
Ashok Kumar Tanwani Department of Histopathology, HBS Medical & Dental College,Islamabad,Pakistan
Maliha Saad Department of Histopathology, HBS Medical & Dental College,Islamabad,Pakistan
Maryam Zulfiqar Department of Histopathology, HBS Medical & Dental College,Islamabad,Pakistan
Maryam Waqar Department of Histopathology, HBS Medical & Dental College,Islamabad,Pakistan
Abstract
Objective: To compare the frequency of expression of p53 in different grades of glioma. Methodology: This descriptive, cross-sectional study was conducted at Pakistan Institute of Medical Sciences from January to December 2019. We included 65 glial neoplasms categorized as astrocytomas, oligodendrogliomas and ependymomas and were graded into low grade and high grade. Brown colored nuclear staining of p53 was interpreted as: - =10% cells +ve, no staining, 10-25% cells +ve, weak intensity, 2650% +ve, Moderate intensity and >51% +ve strong intensity. Data analysis was done using SPSS version 23. Results: Out of 65 patients, 41 (63.1%) were males and 24 (36.9%) females. Age range was 13-75 years (mean 39.3±14.6). Type of gliomas were as follows: astrocytomas 51 (78.4%), oligodendroglioma and ependymomas 7 each (10.8%). High grade gliomas were 26 (40%) while low grade gliomas were 39 (60%). Frequency of p53 expression in glial neoplasms was 52.3%. Stratification for type and grade of glioma was carried out and no correlation was found. Conclusion:  The frequency of p53 expression in glial neoplasms was 52.3%. The p53 expression was more common among low grade astrocytomas. 
Publication Details
Page(s) 557-560
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 49, Issue: 3, Year: 2024

Request the full text from PASTIC

Keywords
p53, ependymomas, Astrocytomas, gliomas., Oligodendrogliomas
References
Mesfin FB,Al-Dhahir MA,Available MA . .Treasure Island (FL): StatPearls Publishing; 2023 Jan-. [Updated 2023 May, 20 : .
Subramanian S,Ahmad T,Available T . .Treasure Island (FL): StatPearls Publishing; 2023 Jan-. [Updated 2023 Aug, 8 : .
Kimberly D,Miller MPH,Quinn T. Brain .2021 .and other central nervous system tumor statistics. Can J Clin, 71 : 381-406.
Fact CBTRUS .2022 .› cbtrus-fact-sheet-2022. , : .
Enam SA,Shah MM,Bajwa MH .2022 .Pakistan Brain Tumour Consortium; Siddiqi S; Pakistan Brain Tumour Consortium Group Names. The Pakistan Brain Tumour Epidemiology Study. J Pak Med Assoc, 72 : S4-S11.
Louis DN,Perry A,Reifenberger G. .2016 .The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol, 13 : 803-20.
Noor H,Briggs NE,McDonald KL .2021 .TP53 Mutation is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy. Cancers, 13 : 5362.
Jin Y,Xiao W,Song T.,Expression T. .2016 .and prognostic significance of p53 in glioma patients: a meta-analysis. Neurochem Res, 41 : 1723-31.
Dho YS,Jung KW,Ha J .2017 .. Brain Tumor Res Treat, 5 : 16-23.
Hu J,Cao J,Topatana W. .2021 .Targeting mutant p53 for cancer therapy: direct and indirect strategies. J Hematol Oncol, 14 : 157-9.
Mantovani F,Collavin L,Del Sal G .2019 .Mutant p53 as a guardian of the cancer cell. Cell Death Differ, 26 : 199-12.
Zhu G,Pan C,Bei JX,Therapies Targeted .2020 .Mutant p53 in Cancer Progression. Front. Oncol, 10 : .
Wang GM,Cioffi G,Patil N. .2022 .Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas. Neuro Oncol, 24 : 302-10.
Xiong Y,Zhang Y,Xiong S Y .2020 .A Glance of p53 Functions in Brain Development, Neural Stem Cells, and Brain Cancer. Biology, 9 : 285-9.
Shajani Z,De Abreu FB,Peterson JD .2018 .Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, nonSmall Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing. Neoplasia, 20 : 256-62.
Arif A,Akhtar F,Ahson A .2022 .Immunohistochemical Expression of IDH1, ATRX and P53 in Low Grade Diffuse Gliomas at Armed Forces Institute of Pathology, Rawalpindi. Pak Armed Forces Med J, 72 : 754-57.
Chatterjee D,Radotra BD .2018 .IDH1, ATRX, and BRAFV600E mutation in astrocytic tumors and their significance in patient outcome in north Indian population. Surg Neurol Int, 9 : 29-32.
Zhang Y,Dube C,Gibert M,Jr. M .2018 .The p53 Pathway in Glioblastoma. Cancers, 10 : 297-302.
Geramizadeh B,Kohandel-Shirazi M,Gliosis Reactive .2021 .Soltani A. A Simple Panel of IDH1 and P53 in Differential Diagnosis Between Low-Grade Astrocytoma. Clin Pathol, 14 : .
Guo CF,Zhuang Y,Chen Y.,Doi Y. .2020 .Significance of tumor protein p53 mutation in cellular process and drug selection in brain lower grade (WHO grades II and III) glioma. Biom Med, : 14.
0

Citations

0

Downloads

66

Views